Last reviewed · How we verify
Glimepiride (HOE490)
Glimepiride (HOE490) is a Sulfonylurea Small molecule drug developed by Sanofi. It is currently FDA-approved for Type 2 diabetes mellitus.
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glimepiride (HOE490) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Sulfonylurea |
| Target | Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose levels in patients with type 2 diabetes by increasing endogenous insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Dizziness
- Headache
- Gastrointestinal disturbances
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
- Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients (NA)
- A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria (PHASE4)
- Glimepiride 4 mg Tablets Under Non-Fasting Conditions (PHASE1)
- Glimepiride 4 mg Tablets Under Fasting Conditions (PHASE1)
- Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg (PHASE1)
- Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glimepiride (HOE490) CI brief — competitive landscape report
- Glimepiride (HOE490) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Glimepiride (HOE490)
What is Glimepiride (HOE490)?
How does Glimepiride (HOE490) work?
What is Glimepiride (HOE490) used for?
Who makes Glimepiride (HOE490)?
What drug class is Glimepiride (HOE490) in?
What development phase is Glimepiride (HOE490) in?
What are the side effects of Glimepiride (HOE490)?
What does Glimepiride (HOE490) target?
Related
- Drug class: All Sulfonylurea drugs
- Target: All drugs targeting Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing